DRONEDARONE HYDROCHLORIDE

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H361：태아 또는 생식능력에 손상을 일으킬 것으로 의심됨

• 예방조치문구

  P201：사용 전 취급 설명서를 확보하시오.

  P202：모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P308+P313：노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.

  P405：밀봉하여 저장하시오.

  P501：...에 내용물 / 용기를 폐기 하시오.

DRONEDARONE HYDROCHLORIDE 화학적 특성, 용도, 생산

• 화학적 성질

  Pale Yellow Solid

• 용도

  Dronedarone Hydrochloride can be used for the treatment of atrial fibrillation and atrial flutter in patients who have suffered cardiac arrhythmias.

• Clinical Use

  Dronedarone hydrochloride (also known as SR33589 and marketed as Multaq) is a drug developed by Sanofi-Aventis for cardiac arrhythmias (irregular heartbeat) that was approved by the FDA in July 2009. Dronedarone is used for the treatment of atrial fibrillation and atrial flutter in patients whose hearts have either returned to normal rhythm or who undergo drug therapy or electroshock treatment to maintain normal cardio rhythm. Dronedarone is less lipophilic than amiodarone, exhibits a much smaller volume of distribution and a half-life of 24 h, this stands in contrast to competitor amiodarone’s half-life of several weeks. As a result of these pharmacokinetic characteristics, dronedarone dosing may be less complicated than amiodarone.

DRONEDARONE HYDROCHLORIDE 공급 업체

Global(427)Suppliers